---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-085321"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2024-07-22T23:59:59+00:00"
generated_at: "2026-05-31T18:36:19.752655+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Janux Therapeutics board reshuffles: Lichter resigns, Barrett becomes Chair, Hernday and Dobmeier appointed

## Summary
- Jay Lichter, Ph.D. resigned from the board effective July 19, not due to any disagreement.
- Ron Barrett, Ph.D. appointed as Chairperson of the Board.
- Natasha Hernday (former Seagen CBO) and Eric Dobmeier (former Chinook CEO) join as Class II and III directors.
- New directors received standard equity grants: options for 16,700 shares and RSUs for 5,000 shares each.
- Hernday led Seagen's $43B Pfizer acquisition; Dobmeier led Chinook's $3.5B Novartis sale.

## SEC filing metadata
- accession: 0000950170-24-085321
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2024-07-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017024085321/0000950170-24-085321-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017024085321/janx-20240719.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-085321
- JSON: https://secwatch.observer/filing/0000950170-24-085321.json
- Plain text: https://secwatch.observer/filing/0000950170-24-085321.txt

## Key facts
- Executive change
  Ron Barrett was appointed as Chair of the Board at Janux Therapeutics, Inc..
  - Action: appointed
  - Role: Chair of the Board
  source text: In connection with Dr. Lichter’s resignation, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), Ron Barrett, Ph.D. was appointed as Chair of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817713/000095017024085321/0000950170-24-085321-index.htm
- Executive change
  Jay Lichter resigned as Director and Chairman at Janux Therapeutics, Inc..
  - Action: resigned
  - Role: Director and Chairman
  source text: On July 19, 2024, Jay Lichter, Ph.D. resigned as a member of the Board of Directors (the “Board”) of Janux Therapeutics, Inc. (the “Company”), including his chairmanship of the Board, effective as of such date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817713/000095017024085321/0000950170-24-085321-index.htm
- Executive change
  Natasha Hernday was appointed as Class II Director at Janux Therapeutics, Inc..
  - Action: appointed
  - Role: Class II Director
  source text: On July 19, 2024, the Board, upon the recommendation of the Nominating and Governance Committee, appointed (i) Natasha Hernday as a Class II director of the Company, with a term of office expiring at the Company’s 2026 annual meeting of stockholders, or until her earlier death, resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817713/000095017024085321/0000950170-24-085321-index.htm
- Executive change
  Eric Dobmeier was appointed as Class III Director at Janux Therapeutics, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: and (ii) Eric Dobmeier as a Class III director of the Company, with a term of office expiring at the Company’s 2027 annual meeting of stockholders, or until his earlier death, resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817713/000095017024085321/0000950170-24-085321-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.